

# Summary Report

# 2021

# Financial Highlights

Amounts in  
million EUR,  
unless otherwise  
indicated

	2021	2020	Change
Net sales	20,618	19,566	+ 5 %
Research and development	4,127	3,696	+ 12 %
Personnel expenses	5,692	5,587	+ 2 %
Average number of employees	52,391	51,944	+ 1 %
Operating income	4,705	4,624	+ 2 %
– as % of net sales	22.8	23.6	
Group profit	3,406	3,062	+ 11 %
– as % of net sales	16.5	15.6	
Group equity	19,331	17,307	+ 12 %
Equity ratio	48 %	47 %	
Investments in tangible assets	968	1,046	– 7 %
Depreciation of tangible assets	609	602	+ 1 %

**Net sales by region (in million EUR)**

	2021	2020	Change
Americas	9,147	8,889	+ 3 %
Europe	6,554	5,879	+ 11 %
Asia / Australia / Africa (AAA)	4,917	4,798	+ 2 %

**Net sales by business (in million EUR)**

	2021	2020	Change
Human Pharma	15,294	14,415	+ 6 %
Animal Health	4,295	4,121	+ 4 %
Biopharmaceutical Contract Manufacturing	917	837	+ 10 %
Other sales	33	33	+ 0 %
Discontinued operations	79	160	− 51 %

# Our Company

Boehringer Ingelheim is working on break-through therapies that transform lives, today and for generations to come. The research-driven biopharmaceutical company focuses on diseases for which no satisfactory treatment option exists to date. In Animal Health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies. More than 52,000 employees create value through innovation daily for the three business areas Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

## Average number of employees by region

	2021	2020	Change
Americas	13,187	13,176	+ 0 %
Europe	28,266	27,379	+ 3 %
Asia / Australia / Africa (AAA)	10,938	11,389	- 4 %
	52,391	51,944	+ 1 %

# Human Pharma

## 15,294 million EUR (+6%)

### Top 4 products

#### Net sales (in million EUR)

	2021	Change
JARDIANCE® family	3,940	+26%
OFEV®	2,491	+21%
TRAJENTA® / JENTADUETO®	1,552	+3%
SPIRIVA®	1,548	-14%
PRADAXA®	1,318	-12%


# Animal Health

## 4,295 million EUR (+ 4 %)

### Top 4 products

#### Net sales (in million EUR)


	2021	Change
NEXGARD®	916	+ 14 %
FRONTLINE®	418	+ 3 %
HEARTGARD®	307	– 2 %
INGELVAC CIRCOFLEX® / FLEXCOMBO®	253	– 4 %



## Americas

**9,147 million EUR (+ 3 %)**

The Americas region remained the company's most important sales market with a 44 % share of total sales. The USA is the most important market with sales of 7,552 million EUR.




# Europe

**6,554 million EUR (+ 11 %)**

The Europe region accounted for 32 % of total sales. Germany is the most important market with sales of 1,867 million EUR.





## **Asia/Australia/ Africa (AAA)**

**4,917 million EUR (+ 2%)**

The AAA region's share of total sales was 24 %. Japan is the most important market with sales of 1,475 million EUR.

# Research and Development

Boehringer Ingelheim's focus is on the research and development of innovative medicines and therapies for humans and animals. Innovation is thus decisive for the future of the company.

Boehringer Ingelheim operates major R&D centers for Human Pharma in, among other places, Germany (Biberach), the USA (Ridgefield), and Austria (Vienna), and 18 R&D sites for Animal Health in Europe, Asia, and America.

The company supplements its own broad R&D portfolio with partnerships involving academic institutions, biotech companies, and public research institutions around the world.

## Research and development

	2021	2020
Expenses in million EUR	4,127	3,696
– as % of net sales	20.0	18.9
Human Pharma expenses in million EUR	3,710	3,283
– as % of Human Pharma net sales	24.3	22.8
Animal Health expenses in million EUR	416	412
– as % of Animal Health net sales	9.7	10.0
Average number of employees	10,109	9,504
Investments in tangible assets in million EUR (without investments in infrastructure)	242	181

**If you have any queries or comments, please contact us.**

**C.H. Boehringer Sohn AG & Co. KG**

Binger Strasse 173

55216 Ingelheim

Germany

Telephone + 49 6132 77-0

Fax + 49 6132 72-0

**Contact**

Corporate Affairs

Matthias Reinig

[press@boehringer-ingelheim.com](mailto:press@boehringer-ingelheim.com)

[boehringer-ingelheim.com](http://boehringer-ingelheim.com)

**Issued by**

C.H. Boehringer Sohn AG & Co. KG

**Concept, design, and layout**

3st kommunikation GmbH, Mainz

[www.3st.de](http://www.3st.de)

**Printed by**

Eberl & Koesel GmbH & Co. KG, Altusried-Krugzell

**Copyright**

© C.H. Boehringer Sohn AG & Co. KG, 2022

All rights reserved. No part of this Annual Report 2021 may be reproduced or transmitted in any form or by any means, electronic or photocopy, without permission in writing from C.H. Boehringer Sohn AG & Co. KG. Figures from third parties used in the annual report are based on data available at the time the financial statement was drawn up.